These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6099634)

  • 1. [Further observations on the use of Suloctidil (Sulocton) in the treatment of migraine].
    Prusiński A; Durko A; Głuszcz-Zielińska A; Szymańska R
    Wiad Lek; 1984 Dec; 37(23):1857-9. PubMed ID: 6099634
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical trial of suloctidil (sulocton) for the treatment of migraine (preliminary report)].
    Prusiński A
    Neurol Neurochir Pol; 1981; 15(3):309-11. PubMed ID: 6273762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suloctidil therapy in migraine: an open pilot study.
    Prusiński A; Durko A; Głuszcz-Zielińska A; Szymańska R
    Curr Med Res Opin; 1983; 8(9):631-3. PubMed ID: 6321107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Suloctidil (sulocton) in the treatment of atherosclerotic neurasthenic syndromes].
    Prusiński A; Kotwica S; Niewodniczy A; Split W
    Wiad Lek; 1982 May; 35(3-4):201-5. PubMed ID: 6287740
    [No Abstract]   [Full Text] [Related]  

  • 5. [Suloctidil in the treatment of focal cerebral ischemia].
    Bartko D; Zúzi M; Brezná M; Trávniková M; Porubec V
    Cesk Neurol Neurochir; 1984 Mar; 47(2):103-8. PubMed ID: 6323038
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients.
    Roncucci R; De Hertogh R; Dormandy JA; Doumont J; Gurewich V; Lambelin G; Lansen J; Rottiers R; Souridis E; Van Stalle F; Versee L
    Arzneimittelforschung; 1979; 29(4):682-4. PubMed ID: 582768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent claudication: Suloctidil v.s. placebo treatment.
    Holm J; Lindblad L; Scherstén T; Suurkula M
    Vasa; 1984; 13(2):175-8. PubMed ID: 6331019
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical and instrumental evaluation of patients with chronic peripheral arterial occlusive disease after prolonged administration of suloctidil].
    Gregoratti L; Redaelli G; Limido P; Ghiringhelli L
    Clin Ter; 1982 Sep; 102(6):607-19. PubMed ID: 6291844
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.
    Baro F; Malfroid M; Waegemans T; Cox JP
    Pharmatherapeutica; 1985; 4(6):399-404. PubMed ID: 3001778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
    Moriau M; Col-De Beys C; Pardonge E; Ferrant A
    Thromb Haemost; 1982 Feb; 47(1):27-31. PubMed ID: 6280332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical therapy of chronic obstructive arteriopathy of the lower extremities. A controlled clinical study of suloctidil versus xanthinol].
    Spinella G; Majorana M
    Clin Ter; 1983 Mar; 104(5):375-81. PubMed ID: 6303677
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoro-popliteal PTA.
    Mahler F; Schneider E; Gallino A; Bollinger A
    Vasa; 1987; 16(4):381-5. PubMed ID: 2827398
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic use of a new vasoactive drug in cerebral vascular diseases in elderly patients].
    Petronio G; Scali G; Casa B; Nonis E
    Clin Ter; 1980 Aug; 94(4):427-44. PubMed ID: 6257445
    [No Abstract]   [Full Text] [Related]  

  • 14. Suloctidil: long-term trial in the aged. Study of microcirculation, viscosity, red cell deformability, fibrinolysis and lipid fractions.
    Merchan R; Zurita IE; Martinez JF
    Arzneimittelforschung; 1985; 35(5):855-7. PubMed ID: 2992530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medium term treatment with suloctidil in obliterating arteriopathies of the lower limbs. Personal experience].
    Marongiu G; Dettori G; Gadeddu A; Noya G; Angius P; Biglioli P
    Minerva Cardioangiol; 1983; 31(7-8):407-10. PubMed ID: 6316206
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evaluation of sulocton action in patients with atherosclerotic brain ischemia].
    Karwowski B; Jura E; Krasicka J; Kruszewska J; Laskowska-Studniarska W; Szymchel J; Nielubowiczowa H
    Neurol Neurochir Pol; 1982; 16(4):237-43. PubMed ID: 6292759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of the blood platelets in the atherosclerotic process and clinical use of a new drug, Suloctidil, with anti-aggregating activity].
    Armani U; Piana A
    Arch Maragliano Patol Clin; 1979; 35(2):57-62. PubMed ID: 233645
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of suloctidil therapy on platelet function in patients with on obliterating arteriopathy of the lower limbs].
    Davì G; Pinto A; Novo S; Avellone G; Galati D; Mazzola A
    Clin Ter; 1982 Oct; 103(2):131-7. PubMed ID: 6295693
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hemorrheological survey in a group with arteriosclerotic vascular disease treated with suloctidil].
    Caimi G; Catania A; Frazzetta F; Capobianco D; Francavilla G; Romano A; Sarno A
    Ric Clin Lab; 1983; 13 Suppl 3():465-8. PubMed ID: 6324326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trial of a new drug in Raynaud's disease. Clinical and thermographic control].
    Dumoulin J
    Electrodiagn Ther; 1981; 18(4):168-74. PubMed ID: 6279383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.